Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Patent
1993-10-12
1997-01-21
Leguyader, John L.
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
536 231, 536 241, 536 243, 536 2431, 435 6, C07H 2104, A61K 3170
Patent
active
055960901
ABSTRACT:
Antisense oligonucleotides complementary to human mRNAs or pre-mRNAs coding or VCAM-I are used in a therapeutic treatment of sepsis (sepsis, the sepsis syndrome, septic shock and all other manifestations of the sepsis disease, including but not inclusive of, adult respiratory distress syndrome, multi-organ failure, or cardiovascular dysfunction).
REFERENCES:
patent: 5272263 (1993-12-01), Hession et al.
Stein et al. Science 261:1004 (1993).
Milligan et al. J. Med. Chem. 36:1924 (1993).
Uhlmann et al. Chemical Reviews 90:544 (1990).
Chiang et al. J. Biol. Chem. 266:18162 (1991).
Leamon et al. PNAS 88:5572 (1991).
Bradley Matthews O.
Hoke Glenn D.
Lee Che-Hung
Williams Taffy J.
Garvert, Esq. William
LeGuyader John L.
Spevack, Esq. A. D.
The United States of America as represented by the Secretary of
LandOfFree
Antisense oligonucleotides directed against human VCAM-1 RNA does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense oligonucleotides directed against human VCAM-1 RNA, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense oligonucleotides directed against human VCAM-1 RNA will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2325148